×

Sign In

Search
Home

Viridian Therapeutics’ eye disorder drug meets late-stage study goal

By Thomson Reuters Dec 16, 2024 | 6:10 AM

(Reuters) – Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)

Health advocates mount opposition to RFK Jr health job pick

US bond investors brace for 'hawkish cut,' spurn long-term bonds

Meta adds live translation, AI video to Ray-Ban smart glasses

Trump says will he talk to Putin, Zelenskiy about stopping Ukraine war

Universal's Virgin Music Group to buy Downtown Music for $775 million

Reports: Lions RB David Montgomery (MCL) could miss rest of season

Privacy Policy
Terms Of Service

Midwest Communications, Inc.

Copyright © 2024. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.